Skip to content

Maestro Series 100 Implantable Cardiac Pacemaker

by Cardiac Control Systems, Inc.

510(k) K852435

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK852435 Date6 Aug 1985ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

Full name
Ccs Implantable Maestro Series 100 Cardiac Pacema
510(k) Number
FDA Product Code
DXY
Device Class
Class III
Regulation
21 CFR Part 870.3610
Advisory Committee
Cardiovascular
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Maestro Series 100 Implantable Cardiac Pacemaker is an implantable pulse-generator designed to regulate heart rhythm by delivering electrical impulses to the heart muscle. This device is intended for patients with bradycardia or other cardiac conduction disorders requiring artificial pacing to maintain proper heart function.

The device is supplied sterile and intended for single-use implantation by qualified medical professionals in clinical settings. It is classified as a Class III medical device under FDA regulations (DXY, 870.3610) and has received 510(k) clearance through the Traditional pathway. Multiple model variants are registered, each adhering to MRI safety standards for cardiac pacemakers and requiring proper storage in a controlled environment prior to use.

Other devices from Cardiac Control Systems, Inc.

See all devices from Cardiac Control Systems, Inc. →

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What types of patients is the Maestro Series 100 Implantable Cardiac Pacemaker designed to support, and how does it work?

    The Maestro Series 100 is designed for patients with bradycardia or other cardiac conduction disorders that require artificial pacing to maintain proper heart function. It works by delivering regulated electrical impulses to the heart muscle, helping to maintain a consistent and effective heartbeat when the patient’s natural conduction system is insufficient.

  • Is the device intended for single-use or can it be reused after implantation?

    The Maestro Series 100 is explicitly supplied sterile and intended for single-use implantation only. It is not designed for reuse, and any unused portion must be discarded according to medical device disposal protocols.

  • What storage conditions are required for the Maestro Series 100 before use?

    The device must be stored in a controlled environment prior to use, as specified in its regulatory documentation. While exact storage conditions (e.g., temperature, humidity) are not detailed here, proper handling ensures MRI safety compliance and device integrity.

  • Does the Maestro Series 100 come in multiple model variants, and if so, how do they differ?

    Yes, the device includes multiple model variants, each registered under separate FDA identifiers (e.g., FEI numbers). While the exact specifications of each variant are not provided, they all adhere to MRI safety standards for cardiac pacemakers, ensuring compatibility with magnetic resonance imaging procedures.

  • How was the regulatory clearance for this device obtained, and what does that mean for clinicians?

    The Maestro Series 100 received FDA 510(k) clearance through the Traditional pathway, with a decision of *Substantially Equivalent* (SESE) to a predicate device. This means the device was evaluated by the FDA’s Cardiovascular (CV) Advisory Committee and deemed comparable in safety and effectiveness to existing pacemakers, ensuring it meets established regulatory standards for use in clinical settings.